Hyperfine, INC

Hyperfine, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the reelection of directors and ratification of its independent auditor.

Hyperfine, Inc. announced first quarter 2026 financial results, showcasing over 80% year-over-year revenue growth and improved gross margins, driven by accelerating commercial adoption of its portable brain imaging system.

Hyperfine, Inc. has secured a senior secured term loan facility of up to $40.0 million from Horizon Technology Finance Corporation, with an initial draw of $15.0 million and issuance of warrants.

Hyperfine, Inc. announced strong fourth-quarter 2025 revenue growth of 128% and a reduced net loss, driven by increased Swoop system sales and strategic capital raises.

Hyperfine, Inc. announced preliminary, unaudited fourth quarter 2025 revenue of $5.3 million, a 127% increase year-over-year, alongside a 30% reduction in net cash burn.

Hyperfine, Inc. has amended its at-the-market sales agreement, increasing the potential offering to $50 million and adding BTIG, LLC as a sales agent for its Class A common stock.

Hyperfine, Inc. reports a Q3 2025 net loss of $11.0 million on declining sales, while securing $18.4 million in net proceeds from an October 2025 public offering.

Hyperfine, Inc. reported a 30.2% decrease in total sales for the first six months of 2025, alongside new FDA clearances for its AI-powered Swoop system and a $5.2 million capital raise.

Hyperfine's Q1 2025 revenue decreased due to lower device sales, despite cost-cutting measures and international expansion efforts.

Hyperfine Inc. saw a significant increase in revenue and unit sales of its Swoop Portable MR Imaging System in the third quarter of 2024, while continuing to manage operating expenses.

Hyperfine Inc. saw a revenue increase in the second quarter of 2024, driven by device and service sales, while still experiencing a net loss.

Hyperfine Inc. saw a 25% increase in revenue in the first quarter of 2024 compared to the same period last year, driven by higher device sales and service revenue, while also reducing operating expenses.

Hyperfine, Inc. reports continued net losses and negative cash flow for FY 2025 despite significant product innovation and strategic commercial expansion for its AI-powered portable MRI system.

Hyperfine, Inc. reports a 17% increase in total revenues for 2024, driven by higher device sales and service revenue, while implementing cost-saving measures through organizational restructuring.

Hyperfine, Inc.'s 10-K filing outlines the details of its capital stock, including Class A and Class B common stock, preferred stock, and various rights and restrictions, as well as the regulatory environment it operates within.

Director Dan Wolterman was granted 52,600 stock options in Hyperfine, Inc. as part of his compensation package.

Hyperfine, Inc. CFO Brett Hale reported the sale of 6,047 shares of Class A Common Stock to cover tax withholding obligations related to vested restricted stock units.

Hyperfine, Inc. COO Thomas Teisseyre sold 6,047 shares of Class A Common Stock to cover tax withholding obligations related to vested RSUs.

Director Ruth A. Fattori was granted 157,700 stock options in Hyperfine, Inc. as part of an equity compensation arrangement.

Director Dan Wolterman was granted 157,700 stock options in Hyperfine, Inc. as part of his compensation package.

Director John T. Dahldorf was granted 157,700 stock options in Hyperfine, Inc. as part of his compensation.

Hyperfine, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 21, 2026, focusing on director elections and auditor ratification.

Hyperfine, Inc. announces its 2025 Annual Meeting to be held virtually on May 19, 2025, with voting open until May 18, 2025, covering the election of directors and ratification of the company's accounting firm.

Hyperfine, Inc. is set to hold its 2025 annual meeting, highlighting strategic advancements including software launches, market expansion, and financial strengthening to drive future growth.

Hyperfine, Inc. is holding its annual stockholder meeting virtually on June 11, 2024, and has made proxy materials available for review and voting.

Hyperfine, Inc. announces its 2024 annual meeting of stockholders to be held virtually on June 11, 2024, featuring proposals for director elections, auditor ratification, and a sunset amendment to the certificate of incorporation.

The Vanguard Group has filed an amended Schedule 13G, reporting its beneficial ownership in Hyperfine Inc. common stock has fallen to 4.34%.